News

Quintiles' founder heads for the exit after 30-plus years as chairman

Quintiles founder Dennis Gillings is planning to step down from his role as chairman by the end of the year, endorsing the leadership of CEO Tom Pike and transitioning into a more advisory role at the world's largest CRO.

Icon buys a market-access firm for $120M

Irish CRO Icon is expanding its drug launch and marketing services, trading $120 million in cash for MediMedia Pharma Solutions.

TrialReach raises $13.5M to connect patients with studies

London startup TrialReach hauled in $13.5 million in Series B cash, funds that will help expand its technology designed to connect patients with their ideal clinical trials.

Covance ticks up revenue on the eve of a merger

Covance posted a roughly 2% increase in sales last quarter, weeks before merging with LabCorp in a $6 billion deal that management says will help the CRO accelerate its growth.

Drugmakers look to India for drug safety monitoring

India has long been a major player in the development and manufacturing of treatments, but more and more drugmakers are outsourcing the monitoring of on-the-market drugs to vendors in the country.

Astellas gets on the trial transparency train

Japanese pharma giant Astellas is the latest drugmaker to make its clinical trial data available to outside researchers, increasing its R&D transparency but stopping short of some industry trailblazers.

Post-merger Simbec-Orion inks two Phase III deals

Welsh CRO Simbec-Orion has agreed to run two late-stage trials, deals the company says affirm the strategy behind its 2014 merger.

Belgian CRO genae buys an eClinical outfit

Fast-expanding CRO genae is buying into clinical trial technology, acquiring a company that focuses on electronic data capture.

Icon is adding 200 jobs with a new Irish R&D outpost

Irish CRO Icon is plotting a new so-called innovation hub in its native Ireland, planning to hire 200 workers as it builds out a data-minded expansion.

Parexel dials down its 2015 expectations and takes the long view

Despite posting an uptick in revenue last quarter, CRO giant Parexel International is slightly lowering its outlook for fiscal 2015, betting that its backlog of deals will eventually make up for some soft sales.

Parexel moves to pick up laid-off GlaxoSmithKline workers

Parexel is leasing a North Carolina building from GlaxoSmithKline, part of a deal between the two in which the CRO will absorb some researchers on the way out as the drugmaker mounts a major restructuring.

Australian CRO Novotech firms up its Hong Kong presence

Australia's Novotech has made a permanent home in Hong Kong, ditching its old office in favor of a larger space as it works to capitalize on the growing demand for clinical services in the region.

Trial tech outfit goBalto bags $12M to expand around the world

San Francisco's goBalto raised $12 million to push its clinical trial software, designed to expedite study startup.

EMA wants more than 700 drugs suspended over GVK data scandal

The European Medicines Agency is recommending its member states stop selling drugs tied to improprieties at a GVK Biosciences facility in India.

PPD beefs up its Irish outpost with a new biologics lab

PPD has amped up the biologics capabilities at its Irish manufacturing operation, opening a new lab devoted to the development of large-molecule treatments.

Covance pools its early-stage R&D services into one offering

Drug developers commonly deal with a host of CROs as they work their way from preclinical testing to first-in-human trials, a process designed to maximize the strengths of each contractor. But a piecemeal approach to early-stage development can lead to costly delays, according to Covance, which is pitching an all-encompassing offering it claims can seamlessly shuttle molecules from animal studies to Phase II.

Cel-Sci's $50M inVentiv suit heads to trial

Cel-Sci, seeking $50 million from former partner inVentiv Health, will soon get its day in court against the CRO.

Ergomed posts a big year with more in store for 2015

U.K. CRO Ergomed, which often shares the risks and rewards of R&D with its clients, grew its revenue by 14% in 2014, and the company hopes to ride a late-year boom into 2015.

AMRI inks a 10-year NIH deal with $37M on the line

In-transition drug developer AMRI has won a 10-year contract with the National Institutes of Health to help develop and manufacture neurological drugs.

Evotec strikes an R&D deal focused on addiction

The R&D innovators at Evotec have signed a deal to lend their drug discovery muscle to U.K. biotech C4X Discovery, hoping to develop selective drugs that can combat addiction without druggy side effects.